Oncology / Haematology

A Phase III Randomised, double blind, placebo controlled, multicentre study evaluating the efficacy and safety of GDC-9545 combined with Palbociclib in women with estrogen receptor positive, HER2-negative locally advanced or metastatic breast cancer.

Trial Name: persevERA

PI: Dr Jacquelyn Thomson

Who can take part:

• Patient has breast cancer that is positive for ER, and HER2-negative locally advanced (recrurrent or progressed) or metastatic breast cancer.

Exclusion criteria:

• Disease recurrence during or within 12 months of completing prior neoadjuvant or adjuvant treatment with an AI
• Disease recurrence during or within 12 months of completing prior neoadjuvant or adjuvant treatment with any CDK4/6 inhibitor
• Prior treatment with a SERD

For further information please contact Diane Canning – 03 9784 8224

Trial Phase

Non-drug Phase 1 Phase 2 Phase 3 Phase 4